Skip to main content
Journal of Genetic Engineering and Biotechnology
Fig. 3 | Journal of Genetic Engineering and Biotechnology

Fig. 3

From: IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy

Fig. 3

A comparison of dual vs. triple antiviral therapy. A Fibrosis improvement was more noticeable (P = 0.038) in patients treated with SOF/RBV than patients treated with SOF/RBV + Peg-INF. Regarding only non-responders of T allele carriers, B triple treatment (SOF/RBV + Peg-INF) decrease patient’s liver stiffness more efficiently than dual treatment and also zinc administration decrease patient’s liver stiffness in both C SOF/RBV and D SOF/RBV + Peg-INF treatments

Back to article page